Albuterol / Ipratropium
DuoNeb / Combivent Respimat
combinationinhaled (SVN) · inhaled (MDI — Combivent Respimat)Onset: 15 minutes (ipratropium component limits early onset)Duration: 4–6 hours
Mechanism of Action
Combination of beta-2 agonist (albuterol) and anticholinergic (ipratropium). Dual bronchodilation via complementary mechanisms: albuterol relaxes smooth muscle via cAMP; ipratropium blocks muscarinic bronchoconstriction.
Dosing
Adult
DuoNeb SVN: 3 mg albuterol / 0.5 mg ipratropium per 3 mL unit dose q6h. Combivent Respimat MDI: 1 inhalation QID
Acute COPD: may administer q4h during exacerbation
Indications
- COPD exacerbation (acute and maintenance)
- Severe acute bronchospasm requiring additive bronchodilation
Contraindications
- Hypersensitivity to albuterol, ipratropium, atropine, or soya lecithin
- Acute narrow-angle glaucoma (avoid eye contact)
Side Effects
- Combined side effects of both agents
- Dry mouth
- Tachycardia
- Tremor
- Urinary retention
- Paradoxical bronchospasm
Monitoring Parameters
- Heart rate
- SpO2 and breath sounds
- Urinary output
- Intraocular pressure (glaucoma patients)
Drug Interactions
- Same as individual agents
- Other anticholinergics (additive)
- Beta-blockers (antagonize albuterol)
Clinical Pearls
- DuoNeb is a unit-dose vial combining both agents in one nebulizer treatment
- Convenience reduces treatment time vs. two separate nebulizations
- Studies show additive bronchodilation vs. either agent alone in COPD
- Combivent Respimat uses soft-mist technology — different technique from pMDI
- Preferred combination in moderate-to-severe COPD exacerbations
Mnemonic
💡 DuoNeb = Dual attack: Beta-2 + Anticholinergic for COPD
NBRC High-Yield
- Combination SABA + SAMA for COPD exacerbations
- DuoNeb (SVN) and Combivent Respimat (MDI) are the two formulations
- Additive bronchodilation in COPD vs. monotherapy
- Avoid spraying Combivent Respimat in eyes — glaucoma risk